Auriga Partners

Vade Secure SASU specializes in email security software, providing protection against phishing, spear phishing, malware, and ransomware. The company's offerings include solutions such as Vade Secure for Office 365, Isltphishing threat detection for security operations centers, and enterprise cloud and gateway services. Vade Secure employs heuristic filtering to analyze incoming emails in real-time, effectively identifying and neutralizing threats, including zero-day attacks. Additionally, the company manages low-priority emails through its Graymail Management feature, which organizes non-essential communications into a separate folder. Founded in 2008 and headquartered in Hem, France, Vade Secure serves a diverse range of sectors including international shipping, original equipment manufacturers, hosting companies, and enterprises. With a presence in five countries—USA, Canada, France, Hong Kong, and Japan—Vade Secure supports over 500 million mailboxes in 76 countries, ensuring round-the-clock assistance for its clients.

Exeliom is a clinical-stage biopharmaceutical company tackling the use of commensal bacteria as drugs. Their mission is to harness the therapeutic potential of gut microbiota to enable people to lead longer and healthier lives. They are committed to developing the next generation of probiotics: innovative microbial therapies. Exeliom develops a new class of medicines called Live Biotherapeutics based on their growing understanding of the central role of the microbiota in the immune system. The company was founded in 2016 and is headquartered in Dijon, France.

Flash Therapeutics is a gene therapy company focused on developing innovative gene and cell-based therapies through its proprietary lentiviral platform. The company specializes in the manufacture of gene transfer tools, which are essential for creating cellular and animal models used in validating candidate genes and conducting drug screenings. By producing highly concentrated and purified viral vectors, Flash Therapeutics enhances its ability to develop predictive experimental cellular models and genetically modified animals. Its approach incorporates both patented non-integrative technology and integrative lentiviral vectors, positioning the company at the forefront of advancements in gene therapy.

EnobraQ is a start-up created in 2015, from a pre-competitive research project supported by Toulouse White Biotechnology (TWB). Concerned with ecological and economic considerations, EnobraQ develops breakthrough technologies that use CO2 and target markets as diverse as nutrition, agri-food, cosmetics, pharmacology and bioplastics.

Pherecydes Pharma SA is a biotechnology company based in Romainville, France, established in 2006. It specializes in the research and development of lytic bacteriophages, which are natural predators of bacteria, for therapeutic and diagnostic applications, particularly in addressing antibiotic resistance. The company has developed several banks of bacteriophages, including a collection targeting Escherichia coli. Pherecydes Pharma is engaged in innovative approaches to personalized phage therapy, aiming to treat bacterial infections by launching multicenter European trials, such as those evaluating phage therapy for infected burn wounds. This therapeutic strategy allows for the detection and treatment of a wide range of bacterial infections, including multi-resistant and emergent strains, without affecting human cells.

aveni, Inc. specializes in advanced metallization technologies for semiconductor applications, particularly in damascene through silicon vias and micro-electromechanical systems (MEMS). The company offers two primary technologies: Electrografting (eG), a wet electrochemical process that facilitates the growth of high-quality thin films on conducting surfaces, and Chemicalgrafting (cG), which is designed for non-conductive substrates. Both technologies are instrumental in enhancing device performance and yield, making them essential for modern semiconductor manufacturing. Founded in 2001 as a spinoff from the Commissariat à l’énergie atomique et aux énergies alternatives (CEA), aveni has established partnerships with various research and development centers, as well as leading global equipment and device manufacturers. The company operates from its headquarters in Massy, France, and leverages a skilled team of scientists and engineers with expertise in surface science, electrochemistry, and materials science to drive innovation in the field.

Vectalys, expert in gene delivery based on lentiviral vectors, is a private biotech company founded by Pascale Bouillé in 2005. Today, Vectalys counts 25 full-time employees exclusively dedicated to providing lentiviral vectors, cell models, molecular biology strategies and supporting your projects. Vectalys aims to help scientists worldwide understand cellular and molecular mechanisms in order to discover new drugs and therapies. Vectalys has developed a state-of-the-art proprietary technology to provide the highest quality of lentiviral vectors for the transduction of hard-to-transfect cells like primary cells, stem cells and in vivo tissues. Vectalys high quality lentiviral vectors ensure 100% transduction efficiency and non-toxic transduction on any target cells, for example to create predictive models. Because each project is unique, the Vectalys team supports you by providing custom lentiviral vectors for the right application with your gene of interest. Vectalys is also the manufacturer of highly pure ready-to-use lentiviral vectors carrying fluorescent, bioluminescent or gene editing proteins. These products are distributed worldwide. Vectalys is committed to providing solutions that save your time and support your most ambitious projects.

VitaDX International SA, founded in 2009 and based in Rennes, France, specializes in the early diagnosis of bladder cancer. The company leverages artificial intelligence and fluorescence imaging technology to enhance diagnostic accuracy. Its primary product, VisioCyt®, allows for bladder cancer detection through a simple urine sample, improving upon traditional urinary cytology methods. By utilizing advanced imaging and machine learning techniques, VitaDX's solutions enable pathologists and healthcare providers to identify potential bladder abnormalities early, facilitating timely diagnosis and treatment, which can lead to better patient outcomes.

Nosopharm is a young innovative biotechnology company dedicated to anti-infective drug discovery. Nosopharm addresses the unmet medical need of the bacterial multidrug resistance to antibiotics, a very concerning issue for hospital-acquired infections. Nosopharm has set up an innovative anti-infective drug discovery platform based on the medicinal mining of the microbial biodiversity. The company has developed a unique expertise in the screening and the characterization of bioactive secondary metabolites produced by an original microbial bioresource: the bacterial genera Xenorhabdus and Photorhabdus.

TxCell S.A. is a biotechnology company based in Valbonne, France, specializing in cellular immunotherapies that leverage regulatory T cells (Tregs) to address severe chronic inflammatory diseases, autoimmunity, and transplantation challenges. The company develops innovative therapies using Tregs engineered with chimeric antigen receptors (CARs) for various conditions, including TX200, aimed at preventing graft rejection in solid organ transplants, and treatments for autoimmune diseases such as bullous pemphigoid and multiple sclerosis. TxCell is also advancing Ovasave, a therapy for refractory Crohn's disease, having completed an initial study with positive outcomes and planning further clinical trials. The company collaborates with prominent research institutions, including the Lübeck Institute of Experimental Dermatology and the University of British Columbia, to enhance its research and development efforts. TxCell operates as a subsidiary of Sangamo Therapeutics, Inc., continuing its focus on innovative immunotherapy solutions.

One More Company, Inc. specializes in contextual intelligence email services, with its flagship product, Senders™, designed to enhance the email experience for users. Senders™ functions similarly to Caller ID for email, providing recipients with additional information about the sender, thus improving communication across various apps, platforms, and devices. The company, which also developed Trackbuster™, prioritizes user privacy and data security, adopting a "privacy by design" approach throughout its product development. One More Company operates under a business model that emphasizes consumer control and transparency, avoiding reliance on advertising or data monetization. Founded by experienced executives from prominent tech companies, One More Company has offices in New York and Paris and is dedicated to delivering simple, intuitive messaging solutions that prioritize the interests of its users.

Nexthink S.A. is a leader in end-user experience management, focusing on enhancing digital workplaces through real-time analytics and employee feedback. The company provides a comprehensive platform that transforms endpoint data into actionable insights, enabling organizations to identify, diagnose, and resolve issues effectively. Its offerings include solutions for incident and problem management, change management, and a Digital Experience Score that combines quantitative data and user input to assess and enhance the digital workplace experience. Nexthink serves a diverse range of sectors, including education, finance, healthcare, and manufacturing, catering to Global 5000 organizations both in Switzerland and internationally. Established in 2004 and headquartered in Prilly, Switzerland, Nexthink operates across the United States, Europe, the Middle East, and Asia Pacific.

Pylote SAS, established in 2008 and located in Drémil-Lafage, France, specializes in the development of mineral microspheres for various applications. The company operates in the fields of mineral and ceramic chemistry, offering innovative solutions under its "PYCLEAR" brand. Pylote's products are designed to enhance the safety and efficacy of consumer goods across multiple sectors, including pharmaceuticals, cosmetics, luxury items, and food. Their technology focuses on antimicrobial properties, helping to mitigate health risks associated with contaminated surfaces. By integrating these mineral microspheres into everyday products, Pylote aims to deliver greener, cleaner, and safer options for consumers.

aveni, Inc. specializes in advanced metallization technologies for semiconductor applications, particularly in damascene through silicon vias and micro-electromechanical systems (MEMS). The company offers two primary technologies: Electrografting (eG), a wet electrochemical process that facilitates the growth of high-quality thin films on conducting surfaces, and Chemicalgrafting (cG), which is designed for non-conductive substrates. Both technologies are instrumental in enhancing device performance and yield, making them essential for modern semiconductor manufacturing. Founded in 2001 as a spinoff from the Commissariat à l’énergie atomique et aux énergies alternatives (CEA), aveni has established partnerships with various research and development centers, as well as leading global equipment and device manufacturers. The company operates from its headquarters in Massy, France, and leverages a skilled team of scientists and engineers with expertise in surface science, electrochemistry, and materials science to drive innovation in the field.

Pherecydes Pharma SA is a biotechnology company based in Romainville, France, established in 2006. It specializes in the research and development of lytic bacteriophages, which are natural predators of bacteria, for therapeutic and diagnostic applications, particularly in addressing antibiotic resistance. The company has developed several banks of bacteriophages, including a collection targeting Escherichia coli. Pherecydes Pharma is engaged in innovative approaches to personalized phage therapy, aiming to treat bacterial infections by launching multicenter European trials, such as those evaluating phage therapy for infected burn wounds. This therapeutic strategy allows for the detection and treatment of a wide range of bacterial infections, including multi-resistant and emergent strains, without affecting human cells.

CoLucid Pharmaceuticals, Inc. is a biotechnology company based in Research Triangle Park, North Carolina, established in 2005. The company specializes in developing therapies for central nervous system disorders. Its primary product, COL-144, is an anti-migraine agent aimed at treating migraine headaches. Additionally, CoLucid is working on COL-204, a conjugated stigmine platform designed to create novel therapeutic entities for various conditions, including sleep/wake disorders, chronic pain, Alzheimer's disease, and psychiatric disorders. Through its innovative approaches, CoLucid Pharmaceuticals aims to address significant unmet medical needs in the field of neurology.

Pherecydes Pharma SA is a biotechnology company based in Romainville, France, established in 2006. It specializes in the research and development of lytic bacteriophages, which are natural predators of bacteria, for therapeutic and diagnostic applications, particularly in addressing antibiotic resistance. The company has developed several banks of bacteriophages, including a collection targeting Escherichia coli. Pherecydes Pharma is engaged in innovative approaches to personalized phage therapy, aiming to treat bacterial infections by launching multicenter European trials, such as those evaluating phage therapy for infected burn wounds. This therapeutic strategy allows for the detection and treatment of a wide range of bacterial infections, including multi-resistant and emergent strains, without affecting human cells.

Theranexus is a biopharmaceutical company based in Lyon, France, focused on developing drug candidates for central nervous system (CNS) disorders. Established in 2013, the company is advancing its lead drug candidate, THN102, which is currently in Phase II clinical trials for sleep/wake disorders, particularly excessive daytime sleepiness associated with Parkinson's disease. Additionally, Theranexus is developing THN201 for neurocognitive disorders related to Alzheimer's disease and THN101 for neuropathic pain. The company's innovative approach combines two distinct drugs to target both neuronal activity and glial cells, addressing significant medical needs in the treatment of brain disorders.

aveni, Inc. specializes in advanced metallization technologies for semiconductor applications, particularly in damascene through silicon vias and micro-electromechanical systems (MEMS). The company offers two primary technologies: Electrografting (eG), a wet electrochemical process that facilitates the growth of high-quality thin films on conducting surfaces, and Chemicalgrafting (cG), which is designed for non-conductive substrates. Both technologies are instrumental in enhancing device performance and yield, making them essential for modern semiconductor manufacturing. Founded in 2001 as a spinoff from the Commissariat à l’énergie atomique et aux énergies alternatives (CEA), aveni has established partnerships with various research and development centers, as well as leading global equipment and device manufacturers. The company operates from its headquarters in Massy, France, and leverages a skilled team of scientists and engineers with expertise in surface science, electrochemistry, and materials science to drive innovation in the field.

Median Technologies is a company that develops and markets software products and platforms for medical image analysis, focusing on oncology clinical trials and cancer screening. Founded in 2002 and based in Valbonne, France, it offers solutions such as iBiopsy, an AI-powered platform that aids in biomarker identification and patient profiling through CT scan similarity searches, and iSee, which facilitates image analysis and management in clinical trials. The company aims to standardize and automate the interpretation of medical images to enhance the diagnosis of cancer and evaluate treatment responses. Median Technologies serves both drug development and patient care markets, partnering with contract research organizations and Canon to deliver integrated imaging services and innovate new imaging technologies.

Amoeba is focused on developing and commercializing green biocide water treatment chemicals. It offers BIOMEBA, a green biocide that harnesses the biocidal properties of Willaertia magna to treat the bacterial risks encountered in cooling towers.

Nexthink S.A. is a leader in end-user experience management, focusing on enhancing digital workplaces through real-time analytics and employee feedback. The company provides a comprehensive platform that transforms endpoint data into actionable insights, enabling organizations to identify, diagnose, and resolve issues effectively. Its offerings include solutions for incident and problem management, change management, and a Digital Experience Score that combines quantitative data and user input to assess and enhance the digital workplace experience. Nexthink serves a diverse range of sectors, including education, finance, healthcare, and manufacturing, catering to Global 5000 organizations both in Switzerland and internationally. Established in 2004 and headquartered in Prilly, Switzerland, Nexthink operates across the United States, Europe, the Middle East, and Asia Pacific.

Founded in 2009 and based in Lyon, France, Fab’entech is a biopharmaceutical company that specializes in developing and commercializing innovative passive immunotherapeutic solutions. The company focuses on specific polyclonal immunoglobulins [F(ab’)₂] aimed at treating emerging infectious diseases and certain drug intoxications. By utilizing highly purified fragments of horse-specific polyclonal immunoglobulins, Fab’entech provides healthcare institutions with effective therapeutic options for emergency situations. As a member of the LyonBiopôle cluster, the company contributes to advancements in medical technology and immunotherapy.

Wallix Product ( WAB Suite) gives the most effective route to security and compliance by mitigating its users’ biggest security risk – privileged access to IT – in the shortest possible time. WALLIX was founded in 2003 with a simple vision to create the most effective and complete solution to the challenges of managing privileged user access. The result of that vision is Wallix AdminBastion (WAB) Suite, a powerful combination of password, access and session management with detailed monitoring and auditing for privileged users’ activity, that now protects hundreds of customers around the world to mitigate external attacks, to control third party access, to prevent insider threat, or to meet their regulatory compliance.

Convertigo is a privately held company recognized as a “pure player” in the enterprise Mobility market and the first software vendor to distribute its cloud based or on-premise Mobile Application Development Platform (MADP) as Open Source. Convertigo is delivering a secured and scalable disruptive all-in-one solution covering challenging backend enablement, optimized for mobility middle ware and rapid development tools for mobile applications. Convertigo team having high frequency interactions with largest customers and SI is 100% focus on developing platform and mobile oriented new features, industry solutions and practices. It’s disruptive technologies and industry standards’ integration since mobility early ages brings Convertigo to the edge of the Mobile Application Development Platform customers’ requirements. With more of 50.000 installations of its community edition, Convertigo technologies have a proven track record with secured and scalable implementations deployed in global fortune 500 companies in EMEA and North America as Carrefour, Morgan Stanley or BNP Paribas.

eXo Platform SAS is a provider of open-source digital collaboration software that facilitates knowledge sharing and enhances employee engagement across various sectors, including government, financial services, and telecommunications. The company offers a range of products, including eXo Platform, which allows for the development of enterprise social networks, websites, and community portals, as well as GateIn, an open-source portal framework. Its suite of tools includes document management, web content management, workflow management, and social collaboration features. eXo Platform also provides a digital wallet solution for transactions in multiple currencies and utility tokens. Founded in 2003 and headquartered in Paris, France, eXo has expanded its global presence with additional offices in the United States, Vietnam, Tunisia, and Ukraine. The company has established strategic partnerships with organizations such as Red Hat, enhancing its offerings to a diverse clientele.

TxCell S.A. is a biotechnology company based in Valbonne, France, specializing in cellular immunotherapies that leverage regulatory T cells (Tregs) to address severe chronic inflammatory diseases, autoimmunity, and transplantation challenges. The company develops innovative therapies using Tregs engineered with chimeric antigen receptors (CARs) for various conditions, including TX200, aimed at preventing graft rejection in solid organ transplants, and treatments for autoimmune diseases such as bullous pemphigoid and multiple sclerosis. TxCell is also advancing Ovasave, a therapy for refractory Crohn's disease, having completed an initial study with positive outcomes and planning further clinical trials. The company collaborates with prominent research institutions, including the Lübeck Institute of Experimental Dermatology and the University of British Columbia, to enhance its research and development efforts. TxCell operates as a subsidiary of Sangamo Therapeutics, Inc., continuing its focus on innovative immunotherapy solutions.

Stantum, Inc. designs and manufactures multitouch surface controllers. Its products include Lemur, which is a control surface for audio and media applications; and DEXTER, a laptop sized control surface, which is used for controlling digital audio workstations. The company’s products are used by musicians, composers, discjockies, media artists, researchers, and developers. It offers its products through distributors and retailers internationally. The company was formerly known as JazzMutant SAS and changed its name in 2007. Stantum, Inc. was founded in 2002 and is based in Bordeaux, France with a liaison office in Tokyo, Japan.

Nosopharm is a young innovative biotechnology company dedicated to anti-infective drug discovery. Nosopharm addresses the unmet medical need of the bacterial multidrug resistance to antibiotics, a very concerning issue for hospital-acquired infections. Nosopharm has set up an innovative anti-infective drug discovery platform based on the medicinal mining of the microbial biodiversity. The company has developed a unique expertise in the screening and the characterization of bioactive secondary metabolites produced by an original microbial bioresource: the bacterial genera Xenorhabdus and Photorhabdus.

Implanet S.A., together with its subsidiaries, designs, manufactures, and sells implants for orthopedic surgery in France, the United States, Brazil, and internationally. The company offers spinal, arthroscopy, and knee products. Its products include Jazz, Jazz Passer, Jazz Cap SP, Jazz Lock, Jazz Claw, Jazz Standalone, Jazz Frame, and Jazz Screw systems for posterior fixation. The company also offers knee prostheses, such as Madison for conventional surgical techniques. Implanet S.A. was founded in 2006 and is based in Martillac, France.

Genocea Biosciences, Inc. is a biopharmaceutical company specializing in the discovery and development of innovative cancer immunotherapies and vaccines to address significant unmet medical needs. Based in Cambridge, Massachusetts, the company utilizes its proprietary ATLAS platform to profile patients' CD4+ and CD8+ T cell immune responses to identify potential targets within their tumors. Genocea's key programs include GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, GEN-011, a neoantigen adoptive T cell therapy, and GEN-010, a neoantigen vaccine initiative. The company also develops immunotherapies for other conditions, such as GEN-003, which targets genital herpes, and maintains pre-clinical programs focused on personalized cancer vaccines. Through its AnTigen Lead Acquisition System, Genocea is committed to advancing vaccine and immunotherapy solutions for various diseases.

Firalis SAS is a biotechnology company based in Huningue, France, specializing in the discovery and development of biomarker-based diagnostics. Established in 2008, Firalis focuses on inflammatory biomarkers and peripheral biomarkers for the early diagnosis of conditions such as minimal vasculitis, drug-induced organ injuries, and other inflammatory disorders. The company provides diagnostic kits aimed at predicting cardiovascular risks associated with coxibs and offers a range of services including biomarker research strategy design, assay development, sample testing, and data analysis. By leveraging a network of clinical centers of excellence, Firalis aims to enhance disease outcomes and patient comfort while reducing healthcare costs. The company is committed to advancing high-potential projects in biomarker diagnostics, with the goal of launching high-value diagnostic kits in the near future.

Miliboo is a furniture brand that specializes in designing and providing a diverse range of contemporary furniture products. Founded in 2005 and headquartered in Pringy, France, the company offers an extensive portfolio that includes sofas, armchairs, office chairs, dining tables, bar stools, storage solutions, and garden furniture, as well as decor items and furniture for children. Miliboo focuses on modern design and functionality, catering to various customer needs in both indoor and outdoor settings.

Bonitasoft, based in Grenoble, France, specializes in open source business process management (BPM) solutions. Its flagship product, the Bonita platform, facilitates the design, development, execution, and monitoring of business processes, offering tools such as Bonita Studio for graphical process design and the Bonita Execution Engine for integrating services and BPM standards. The platform supports digital operations and IT modernization by enabling automation and optimization of business processes, while also allowing for low-code application development and robotic automation. Bonitasoft provides a cloud-enabled version of its BPM solution, known as BonitaCloud, which offers flexibility for developers to build and run applications in diverse environments. The company caters to a variety of corporate functions, including human resources, finance, quality management, and IT management. Its clientele spans multiple industries, including education, energy, healthcare, financial services, manufacturing, retail, and telecommunications. In addition to software solutions, Bonitasoft offers comprehensive support services, including training, consulting, and implementation assistance.

aveni, Inc. specializes in advanced metallization technologies for semiconductor applications, particularly in damascene through silicon vias and micro-electromechanical systems (MEMS). The company offers two primary technologies: Electrografting (eG), a wet electrochemical process that facilitates the growth of high-quality thin films on conducting surfaces, and Chemicalgrafting (cG), which is designed for non-conductive substrates. Both technologies are instrumental in enhancing device performance and yield, making them essential for modern semiconductor manufacturing. Founded in 2001 as a spinoff from the Commissariat à l’énergie atomique et aux énergies alternatives (CEA), aveni has established partnerships with various research and development centers, as well as leading global equipment and device manufacturers. The company operates from its headquarters in Massy, France, and leverages a skilled team of scientists and engineers with expertise in surface science, electrochemistry, and materials science to drive innovation in the field.

SuperSonic Imagine SA operates as a medical technology company. It designs, develops, and markets Aixplorer, an ultrasound system. It has developed a technology that offers practitioners and patients a breakthrough in the diagnosis and follow up of breast, prostate, and thyroid cancers, as well as liver diseases. The company’s products include Aixplorer, an ultrasound system that renders images with exceptional definition, contrast, and resolution. It operates primarily in China, the United States, and France. The company was founded in 2005 and is headquartered in Aix-en-Provence, France. SuperSonic Imagine SA is a subsidiary of Hologic Hub Ltd.

ERYTECH Pharma S.A. is a clinical-stage biopharmaceutical company based in Lyon, France, founded in 2004. The company specializes in the development of red blood cell-based therapeutics aimed at treating cancer and orphan diseases. Its lead product candidate, eryaspase, is currently undergoing Phase III clinical trials for second-line pancreatic cancer and Phase II trials for triple-negative breast cancer. Additionally, ERYTECH is developing erymethionase, a preclinical candidate targeting methionine-dependent cancers, which consists of methionine-gamma-lyase encapsulated in red blood cells. The company collaborates with research institutions such as the Fox Chase Cancer Center and Queen’s University of Canada to enhance the preclinical development of its products for conditions like homocystinuria and arginase-1 deficiency, respectively. Through its innovative approach to encapsulating therapeutic molecules, ERYTECH Pharma aims to improve the efficacy and safety of its treatments.

Population Genetics Technologies creates products that accelerate large-scale population studies, through the simultaneous analysis of multiple individual genomes. Their proprietary technology replaces initial sample preparation steps for next-generation DNA sequencing, overcoming cost barriers and practical constraints that limit discovery.

Codenvy is a provider of a cloud development platform designed for coding, building and testing applications.The company's cloud development environment takes the local desktop workspace, which consists of the editor, builder and tester runtimes and separates it logically from its underlying physical environment and moves it into the cloud, enabling enterprises to access workspaces that are on-demand, collaborative and constraint-free.

TxCell S.A. is a biotechnology company based in Valbonne, France, specializing in cellular immunotherapies that leverage regulatory T cells (Tregs) to address severe chronic inflammatory diseases, autoimmunity, and transplantation challenges. The company develops innovative therapies using Tregs engineered with chimeric antigen receptors (CARs) for various conditions, including TX200, aimed at preventing graft rejection in solid organ transplants, and treatments for autoimmune diseases such as bullous pemphigoid and multiple sclerosis. TxCell is also advancing Ovasave, a therapy for refractory Crohn's disease, having completed an initial study with positive outcomes and planning further clinical trials. The company collaborates with prominent research institutions, including the Lübeck Institute of Experimental Dermatology and the University of British Columbia, to enhance its research and development efforts. TxCell operates as a subsidiary of Sangamo Therapeutics, Inc., continuing its focus on innovative immunotherapy solutions.

Genocea Biosciences, Inc. is a biopharmaceutical company specializing in the discovery and development of innovative cancer immunotherapies and vaccines to address significant unmet medical needs. Based in Cambridge, Massachusetts, the company utilizes its proprietary ATLAS platform to profile patients' CD4+ and CD8+ T cell immune responses to identify potential targets within their tumors. Genocea's key programs include GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, GEN-011, a neoantigen adoptive T cell therapy, and GEN-010, a neoantigen vaccine initiative. The company also develops immunotherapies for other conditions, such as GEN-003, which targets genital herpes, and maintains pre-clinical programs focused on personalized cancer vaccines. Through its AnTigen Lead Acquisition System, Genocea is committed to advancing vaccine and immunotherapy solutions for various diseases.

Population Genetics Technologies creates products that accelerate large-scale population studies, through the simultaneous analysis of multiple individual genomes. Their proprietary technology replaces initial sample preparation steps for next-generation DNA sequencing, overcoming cost barriers and practical constraints that limit discovery.

Domain Therapeutics SA is a biopharmaceutical company based in Illkirch-Graffenstaden, France, focused on the discovery and early development of therapeutic drugs targeting G Protein-Coupled Receptors (GPCRs), which are key drug targets in various diseases. The company specializes in developing treatments for Central Nervous System (CNS) disorders and cancer. Utilizing its proprietary DTect-All technology, Domain Therapeutics identifies both orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs), which are not discoverable through conventional methods. This innovative approach allows the company to address challenging GPCRs, including orphan and peptidic receptors. Founded in 2001, the company was previously known as Faust Pharmaceuticals SA before rebranding in December 2008.

Wallix Product ( WAB Suite) gives the most effective route to security and compliance by mitigating its users’ biggest security risk – privileged access to IT – in the shortest possible time. WALLIX was founded in 2003 with a simple vision to create the most effective and complete solution to the challenges of managing privileged user access. The result of that vision is Wallix AdminBastion (WAB) Suite, a powerful combination of password, access and session management with detailed monitoring and auditing for privileged users’ activity, that now protects hundreds of customers around the world to mitigate external attacks, to control third party access, to prevent insider threat, or to meet their regulatory compliance.

Gamida Cell Ltd. is a clinical-stage biopharmaceutical company focused on developing innovative cell therapies for blood cancers and serious blood diseases. The company's lead product candidate, omidubicel, utilizes expanded hematopoietic stem cells and differentiated immune cells, and is currently undergoing Phase 3 trials for high-risk hematologic malignancies, alongside Phase 1/2 trials for severe aplastic anemia. Additionally, Gamida Cell is advancing GDA-201, a natural killer cell-based immunotherapy, which is in Phase 1/2 studies for relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Founded in 1998 and headquartered in Jerusalem, Israel, the company leverages a proprietary expansion platform that enhances the therapeutic potential of umbilical cord blood-derived cells and natural killer cells, aiming to address significant unmet clinical needs in the field of regenerative medicine.

Eptica S.A. specializes in customer relationship management (CRM) software tailored for business-to-business (B2B) marketplaces. Founded in 2001 and headquartered in Boulogne-Billancourt, France, the company focuses on facilitating real-time interactions between enterprises and their clients, suppliers, and partners through various digital channels including email, social media, web chat, and agent communications. Eptica offers both on-premise and Software as a Service (SaaS) solutions, enhancing customer engagement and operational efficiency by delivering timely, personalized responses. The platform is built around a central knowledge base and incorporates advanced linguistic services to interpret the tone and context of interactions. Eptica serves a diverse clientele across sectors such as banking, insurance, retail, tourism, and public institutions, with over 410 organizations in 15 countries utilizing its services. As a subsidiary of Enghouse Systems Limited, Eptica continues to innovate and has been recognized in Gartner's CRM Magic Quadrants for four consecutive years.

AMPLITUDE TECHNOLOGIES is the global expert in the science, design and manufacture of high performance laser systems for a variety of specialist applications. ln addition to systems used for fundamental physics research, the company is a leading authority in the medical research domain including radiography and cancer treatment projects. AMPLITUDE TECHNOLOGIES offers worldwide project management experience. Its comprehensive project management program provides industry-leading levels of customer support. From the first steps of the design concept, to laboratory installation, training and ongoing after-sales requirements, the Amplitude team is on-hand to provide the support the application demands. Over a decade' s experience in the Science, design and development, and support of state-of-the-art systems in the field means that every AMPLITUDE TECHNOLOGIES system is engineered to be extremely robust and reliable, offering unparalleled performance no matter what the application.

Neolane, Inc. is a conversational marketing technology provider, which develops marketing automation and cross-channel campaign management software and services for business-to-business and business-to-consumer marketers. In 2012, Neolane recorded $58 million in revenue representing 40% year-over-year growth. In 2013, Neolane was named #64 on the Forbes list of America's Most Promising companies. Neolane provides the only conversational marketing technology that empowers organizations to build and sustain one-to-one lifetime dialogues, dramatically increasing revenue and marketing efficiency. Neolane has a track record of enabling its customers to adapt to new customer engagement challenges and exploit opportunities more quickly than their competition. Neolane is used by more than 400 of the world's leading companies including Alcatel Lucent, barnesandnoble.com, Orange, Sears Canada, Sephora Europe, and Sony Music.

Fashion Brand selling only fully customizable item under the MoodbyMe brand.

CYTOO focuses on innovative products for the life science research market with an emphasis in cell based assays, high content analysis and cell screening. They develop, manufacture, and distribute products that make cellular analysis robust and reliable by dramatically decreasing cell variability. There new micropattern-based products are designed to meet the needs of all clients whatever their research goals. They are open to suggestions or specific requests that can improve and spread the scope of this breakthrough in quantitative cell analysis.

Wallix Product ( WAB Suite) gives the most effective route to security and compliance by mitigating its users’ biggest security risk – privileged access to IT – in the shortest possible time. WALLIX was founded in 2003 with a simple vision to create the most effective and complete solution to the challenges of managing privileged user access. The result of that vision is Wallix AdminBastion (WAB) Suite, a powerful combination of password, access and session management with detailed monitoring and auditing for privileged users’ activity, that now protects hundreds of customers around the world to mitigate external attacks, to control third party access, to prevent insider threat, or to meet their regulatory compliance.

Population Genetics Technologies creates products that accelerate large-scale population studies, through the simultaneous analysis of multiple individual genomes. Their proprietary technology replaces initial sample preparation steps for next-generation DNA sequencing, overcoming cost barriers and practical constraints that limit discovery.

Bonitasoft, based in Grenoble, France, specializes in open source business process management (BPM) solutions. Its flagship product, the Bonita platform, facilitates the design, development, execution, and monitoring of business processes, offering tools such as Bonita Studio for graphical process design and the Bonita Execution Engine for integrating services and BPM standards. The platform supports digital operations and IT modernization by enabling automation and optimization of business processes, while also allowing for low-code application development and robotic automation. Bonitasoft provides a cloud-enabled version of its BPM solution, known as BonitaCloud, which offers flexibility for developers to build and run applications in diverse environments. The company caters to a variety of corporate functions, including human resources, finance, quality management, and IT management. Its clientele spans multiple industries, including education, energy, healthcare, financial services, manufacturing, retail, and telecommunications. In addition to software solutions, Bonitasoft offers comprehensive support services, including training, consulting, and implementation assistance.

Implanet S.A., together with its subsidiaries, designs, manufactures, and sells implants for orthopedic surgery in France, the United States, Brazil, and internationally. The company offers spinal, arthroscopy, and knee products. Its products include Jazz, Jazz Passer, Jazz Cap SP, Jazz Lock, Jazz Claw, Jazz Standalone, Jazz Frame, and Jazz Screw systems for posterior fixation. The company also offers knee prostheses, such as Madison for conventional surgical techniques. Implanet S.A. was founded in 2006 and is based in Martillac, France.

ERYTECH Pharma S.A. is a clinical-stage biopharmaceutical company based in Lyon, France, founded in 2004. The company specializes in the development of red blood cell-based therapeutics aimed at treating cancer and orphan diseases. Its lead product candidate, eryaspase, is currently undergoing Phase III clinical trials for second-line pancreatic cancer and Phase II trials for triple-negative breast cancer. Additionally, ERYTECH is developing erymethionase, a preclinical candidate targeting methionine-dependent cancers, which consists of methionine-gamma-lyase encapsulated in red blood cells. The company collaborates with research institutions such as the Fox Chase Cancer Center and Queen’s University of Canada to enhance the preclinical development of its products for conditions like homocystinuria and arginase-1 deficiency, respectively. Through its innovative approach to encapsulating therapeutic molecules, ERYTECH Pharma aims to improve the efficacy and safety of its treatments.

Isocell SA is a biotechnology company based in Paris, France, specializing in the development and manufacture of nutritional supplements. The company offers a range of products designed to support health and well-being, including GliSODine VITALITE for energy recovery, GliSODin COMPLEX, which protects the activity of SuperOxide Dismutase in intestinal cells, and GliSODine, an antioxidant that combats oxidative stress related to aging. Additionally, Isocell provides GliSODine DEFENSES to enhance immune function, GliSODine DRAINANTE to aid digestion and detoxification, and GliSODine MOISTURIZING for skin health. Other offerings include GliSODine SOLAIRE, which prepares the skin for sun exposure, and GliSODine DETOXIFIANTE for overall purification and revitalization. Founded in 2001, Isocell serves customers in France and internationally, including markets in the United States, Japan, and Europe. The company also has a professional line of nutricosmetics known as GliSODin Skin Nutrients, launched in 2008, which focuses on providing essential nutrients to protect the skin from oxidative stress.

Availpro SAS develops and delivers e-booking software solutions that allow hotels to increase their occupancy and revenue. It offers Smart Booking Engine, a solution to increase sales on website; Facebook Booking Engine, a solution to boost hotel’s social sales and promote special offers; Mobile Booking Engine, a solution to make mobile sales a reality; Smart Channel Manager, a solution to manage availability rooms and rates with a single planner; and PMS/CRS connectivity, a solution to convert availability into bookings. The company also provides GDS connectivity, a solution to sell rooms directly through travel agencies; RateScreener/Parity Checker, a solution to analyze and compare competitors’ rates; NextRate, a solution to optimize and sell at the right price; Guest Reviews, a solution to improve guest satisfaction; and Sentinel, a solution to monitor and analyze hotel’s online reputation. It serves independent hotels, hotel chains and hotel groups, and aparthotels. Availpro SAS was formerly known as Siriona S.A. The company was founded in 2001 and is based in Paris, France with sales offices in Europe. As of April 5, 2017, Availpro SAS operates as a subsidiary of Accor SA.

They believe that conventional diabetes care technology is stuck in the past, and that it has failed to put first the needs and wants of patients who have to live with the condition and the daily demands of its treatment. Those with diabetes should be put back in control, and they should live a life that is as unaffected as possible by the need to manage their condition. The experience of managing diabetes should be as positive as possible. Thoughtful and innovative design should make things easier to understand and simpler to use. With belief in these ideals, they tore up convention. When they started, they did so with a focus only on how modern technology and beautiful design would make life easier for someone managing diabetes.

Miliboo is a furniture brand that specializes in designing and providing a diverse range of contemporary furniture products. Founded in 2005 and headquartered in Pringy, France, the company offers an extensive portfolio that includes sofas, armchairs, office chairs, dining tables, bar stools, storage solutions, and garden furniture, as well as decor items and furniture for children. Miliboo focuses on modern design and functionality, catering to various customer needs in both indoor and outdoor settings.

Population Genetics Technologies creates products that accelerate large-scale population studies, through the simultaneous analysis of multiple individual genomes. Their proprietary technology replaces initial sample preparation steps for next-generation DNA sequencing, overcoming cost barriers and practical constraints that limit discovery.

Median Technologies is a company that develops and markets software products and platforms for medical image analysis, focusing on oncology clinical trials and cancer screening. Founded in 2002 and based in Valbonne, France, it offers solutions such as iBiopsy, an AI-powered platform that aids in biomarker identification and patient profiling through CT scan similarity searches, and iSee, which facilitates image analysis and management in clinical trials. The company aims to standardize and automate the interpretation of medical images to enhance the diagnosis of cancer and evaluate treatment responses. Median Technologies serves both drug development and patient care markets, partnering with contract research organizations and Canon to deliver integrated imaging services and innovate new imaging technologies.

SuperSonic Imagine SA operates as a medical technology company. It designs, develops, and markets Aixplorer, an ultrasound system. It has developed a technology that offers practitioners and patients a breakthrough in the diagnosis and follow up of breast, prostate, and thyroid cancers, as well as liver diseases. The company’s products include Aixplorer, an ultrasound system that renders images with exceptional definition, contrast, and resolution. It operates primarily in China, the United States, and France. The company was founded in 2005 and is headquartered in Aix-en-Provence, France. SuperSonic Imagine SA is a subsidiary of Hologic Hub Ltd.

Eve.com specializes in massively multiplayer online roleplaying games (MMORPGs), boasting a diverse portfolio that includes popular titles such as Eve Online, Eve Valkyrie, Gunjack, Dust 514, and Eve Universe. The company focuses on creating immersive gaming experiences that engage players in expansive virtual worlds, fostering community interaction and collaboration. Through its innovative approach to game design and storytelling, Eve.com has established a strong presence in the gaming industry, appealing to a dedicated audience of gamers.

Nexthink S.A. is a leader in end-user experience management, focusing on enhancing digital workplaces through real-time analytics and employee feedback. The company provides a comprehensive platform that transforms endpoint data into actionable insights, enabling organizations to identify, diagnose, and resolve issues effectively. Its offerings include solutions for incident and problem management, change management, and a Digital Experience Score that combines quantitative data and user input to assess and enhance the digital workplace experience. Nexthink serves a diverse range of sectors, including education, finance, healthcare, and manufacturing, catering to Global 5000 organizations both in Switzerland and internationally. Established in 2004 and headquartered in Prilly, Switzerland, Nexthink operates across the United States, Europe, the Middle East, and Asia Pacific.

ERYTECH Pharma S.A. is a clinical-stage biopharmaceutical company based in Lyon, France, founded in 2004. The company specializes in the development of red blood cell-based therapeutics aimed at treating cancer and orphan diseases. Its lead product candidate, eryaspase, is currently undergoing Phase III clinical trials for second-line pancreatic cancer and Phase II trials for triple-negative breast cancer. Additionally, ERYTECH is developing erymethionase, a preclinical candidate targeting methionine-dependent cancers, which consists of methionine-gamma-lyase encapsulated in red blood cells. The company collaborates with research institutions such as the Fox Chase Cancer Center and Queen’s University of Canada to enhance the preclinical development of its products for conditions like homocystinuria and arginase-1 deficiency, respectively. Through its innovative approach to encapsulating therapeutic molecules, ERYTECH Pharma aims to improve the efficacy and safety of its treatments.

Ekinops is a provider of advanced optical transport solutions tailored for service providers and private networks globally. The company specializes in its EKINOPS 360 platform, which is designed for a variety of applications, including metro, regional, and long-haul communications. Ekinops offers a range of carrier-grade solutions, including 10G, 100G, and 200G options that enhance data transport capacity. Its expertise in transmission, aggregation, and Forward Error Correction (FEC) enables operators to efficiently utilize dark fiber and various network technologies such as CWDM, DWDM, SONET/SDH, IP, and SAN networks.

Implanet S.A., together with its subsidiaries, designs, manufactures, and sells implants for orthopedic surgery in France, the United States, Brazil, and internationally. The company offers spinal, arthroscopy, and knee products. Its products include Jazz, Jazz Passer, Jazz Cap SP, Jazz Lock, Jazz Claw, Jazz Standalone, Jazz Frame, and Jazz Screw systems for posterior fixation. The company also offers knee prostheses, such as Madison for conventional surgical techniques. Implanet S.A. was founded in 2006 and is based in Martillac, France.

eXo Platform SAS is a provider of open-source digital collaboration software that facilitates knowledge sharing and enhances employee engagement across various sectors, including government, financial services, and telecommunications. The company offers a range of products, including eXo Platform, which allows for the development of enterprise social networks, websites, and community portals, as well as GateIn, an open-source portal framework. Its suite of tools includes document management, web content management, workflow management, and social collaboration features. eXo Platform also provides a digital wallet solution for transactions in multiple currencies and utility tokens. Founded in 2003 and headquartered in Paris, France, eXo has expanded its global presence with additional offices in the United States, Vietnam, Tunisia, and Ukraine. The company has established strategic partnerships with organizations such as Red Hat, enhancing its offerings to a diverse clientele.

Fashion Brand selling only fully customizable item under the MoodbyMe brand.

Evolva Holding SA is a biotechnology company based in Switzerland that specializes in discovering, developing, and commercializing innovative ingredients for various sectors, including food, nutrition, personal healthcare, and agriculture. Founded in 2004, the company leverages a proprietary synthetic biology technology platform to create high-quality ingredients that mirror the properties of natural products while eliminating their drawbacks. Evolva's product portfolio includes branded ingredients like Veri-te Resveratrol, used for age-related health, and EverSweet Stevia, a natural sweetener. Additionally, the company offers Nootkashield for pest control, EveNootkatone for flavor and fragrance applications, and EveValencene, a citrus flavoring. Evolva serves diverse markets, including nutrition, flavors and fragrances, animal health, personal care, and pharmaceuticals, both developing its own products and collaborating with other industry players.

Genocea Biosciences, Inc. is a biopharmaceutical company specializing in the discovery and development of innovative cancer immunotherapies and vaccines to address significant unmet medical needs. Based in Cambridge, Massachusetts, the company utilizes its proprietary ATLAS platform to profile patients' CD4+ and CD8+ T cell immune responses to identify potential targets within their tumors. Genocea's key programs include GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, GEN-011, a neoantigen adoptive T cell therapy, and GEN-010, a neoantigen vaccine initiative. The company also develops immunotherapies for other conditions, such as GEN-003, which targets genital herpes, and maintains pre-clinical programs focused on personalized cancer vaccines. Through its AnTigen Lead Acquisition System, Genocea is committed to advancing vaccine and immunotherapy solutions for various diseases.

Evolva Holding SA is a biotechnology company based in Switzerland that specializes in discovering, developing, and commercializing innovative ingredients for various sectors, including food, nutrition, personal healthcare, and agriculture. Founded in 2004, the company leverages a proprietary synthetic biology technology platform to create high-quality ingredients that mirror the properties of natural products while eliminating their drawbacks. Evolva's product portfolio includes branded ingredients like Veri-te Resveratrol, used for age-related health, and EverSweet Stevia, a natural sweetener. Additionally, the company offers Nootkashield for pest control, EveNootkatone for flavor and fragrance applications, and EveValencene, a citrus flavoring. Evolva serves diverse markets, including nutrition, flavors and fragrances, animal health, personal care, and pharmaceuticals, both developing its own products and collaborating with other industry players.

Pharma Omnium is a French pharmaceutical company that markets mature drugs in various therapeutic classes. The company provides nutraceutical, dermatological, and dermo-esthetic products.

CYTOO focuses on innovative products for the life science research market with an emphasis in cell based assays, high content analysis and cell screening. They develop, manufacture, and distribute products that make cellular analysis robust and reliable by dramatically decreasing cell variability. There new micropattern-based products are designed to meet the needs of all clients whatever their research goals. They are open to suggestions or specific requests that can improve and spread the scope of this breakthrough in quantitative cell analysis.

Santen is a pharmaceutical company specializing in the development and manufacture of ophthalmic products. With over 120 years of experience, it focuses primarily on prescription ophthalmic pharmaceuticals, which includes both prescription and over-the-counter medications. Santen also has a segment dedicated to medical devices. The company has a strong global presence, with clinical development networks across Europe, Japan, and the United States, and most of its revenue is generated from Japan and other Asian markets. Through dedicated research and collaboration, Santen aims to address unmet needs in ophthalmology, continuously innovating to enhance the quality of life for patients worldwide.

Bonitasoft, based in Grenoble, France, specializes in open source business process management (BPM) solutions. Its flagship product, the Bonita platform, facilitates the design, development, execution, and monitoring of business processes, offering tools such as Bonita Studio for graphical process design and the Bonita Execution Engine for integrating services and BPM standards. The platform supports digital operations and IT modernization by enabling automation and optimization of business processes, while also allowing for low-code application development and robotic automation. Bonitasoft provides a cloud-enabled version of its BPM solution, known as BonitaCloud, which offers flexibility for developers to build and run applications in diverse environments. The company caters to a variety of corporate functions, including human resources, finance, quality management, and IT management. Its clientele spans multiple industries, including education, energy, healthcare, financial services, manufacturing, retail, and telecommunications. In addition to software solutions, Bonitasoft offers comprehensive support services, including training, consulting, and implementation assistance.

Convertigo is a privately held company recognized as a “pure player” in the enterprise Mobility market and the first software vendor to distribute its cloud based or on-premise Mobile Application Development Platform (MADP) as Open Source. Convertigo is delivering a secured and scalable disruptive all-in-one solution covering challenging backend enablement, optimized for mobility middle ware and rapid development tools for mobile applications. Convertigo team having high frequency interactions with largest customers and SI is 100% focus on developing platform and mobile oriented new features, industry solutions and practices. It’s disruptive technologies and industry standards’ integration since mobility early ages brings Convertigo to the edge of the Mobile Application Development Platform customers’ requirements. With more of 50.000 installations of its community edition, Convertigo technologies have a proven track record with secured and scalable implementations deployed in global fortune 500 companies in EMEA and North America as Carrefour, Morgan Stanley or BNP Paribas.

Implanet S.A., together with its subsidiaries, designs, manufactures, and sells implants for orthopedic surgery in France, the United States, Brazil, and internationally. The company offers spinal, arthroscopy, and knee products. Its products include Jazz, Jazz Passer, Jazz Cap SP, Jazz Lock, Jazz Claw, Jazz Standalone, Jazz Frame, and Jazz Screw systems for posterior fixation. The company also offers knee prostheses, such as Madison for conventional surgical techniques. Implanet S.A. was founded in 2006 and is based in Martillac, France.

Ekinops is a provider of advanced optical transport solutions tailored for service providers and private networks globally. The company specializes in its EKINOPS 360 platform, which is designed for a variety of applications, including metro, regional, and long-haul communications. Ekinops offers a range of carrier-grade solutions, including 10G, 100G, and 200G options that enhance data transport capacity. Its expertise in transmission, aggregation, and Forward Error Correction (FEC) enables operators to efficiently utilize dark fiber and various network technologies such as CWDM, DWDM, SONET/SDH, IP, and SAN networks.

Population Genetics Technologies creates products that accelerate large-scale population studies, through the simultaneous analysis of multiple individual genomes. Their proprietary technology replaces initial sample preparation steps for next-generation DNA sequencing, overcoming cost barriers and practical constraints that limit discovery.

Stantum, Inc. designs and manufactures multitouch surface controllers. Its products include Lemur, which is a control surface for audio and media applications; and DEXTER, a laptop sized control surface, which is used for controlling digital audio workstations. The company’s products are used by musicians, composers, discjockies, media artists, researchers, and developers. It offers its products through distributors and retailers internationally. The company was formerly known as JazzMutant SAS and changed its name in 2007. Stantum, Inc. was founded in 2002 and is based in Bordeaux, France with a liaison office in Tokyo, Japan.

Genocea Biosciences, Inc. is a biopharmaceutical company specializing in the discovery and development of innovative cancer immunotherapies and vaccines to address significant unmet medical needs. Based in Cambridge, Massachusetts, the company utilizes its proprietary ATLAS platform to profile patients' CD4+ and CD8+ T cell immune responses to identify potential targets within their tumors. Genocea's key programs include GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, GEN-011, a neoantigen adoptive T cell therapy, and GEN-010, a neoantigen vaccine initiative. The company also develops immunotherapies for other conditions, such as GEN-003, which targets genital herpes, and maintains pre-clinical programs focused on personalized cancer vaccines. Through its AnTigen Lead Acquisition System, Genocea is committed to advancing vaccine and immunotherapy solutions for various diseases.

SuperSonic Imagine SA operates as a medical technology company. It designs, develops, and markets Aixplorer, an ultrasound system. It has developed a technology that offers practitioners and patients a breakthrough in the diagnosis and follow up of breast, prostate, and thyroid cancers, as well as liver diseases. The company’s products include Aixplorer, an ultrasound system that renders images with exceptional definition, contrast, and resolution. It operates primarily in China, the United States, and France. The company was founded in 2005 and is headquartered in Aix-en-Provence, France. SuperSonic Imagine SA is a subsidiary of Hologic Hub Ltd.

Pharma Omnium is a French pharmaceutical company that markets mature drugs in various therapeutic classes. The company provides nutraceutical, dermatological, and dermo-esthetic products.

Bag Tech develops, designs, and manufactures a variety of bags.

Population Genetics Technologies creates products that accelerate large-scale population studies, through the simultaneous analysis of multiple individual genomes. Their proprietary technology replaces initial sample preparation steps for next-generation DNA sequencing, overcoming cost barriers and practical constraints that limit discovery.

TxCell S.A. is a biotechnology company based in Valbonne, France, specializing in cellular immunotherapies that leverage regulatory T cells (Tregs) to address severe chronic inflammatory diseases, autoimmunity, and transplantation challenges. The company develops innovative therapies using Tregs engineered with chimeric antigen receptors (CARs) for various conditions, including TX200, aimed at preventing graft rejection in solid organ transplants, and treatments for autoimmune diseases such as bullous pemphigoid and multiple sclerosis. TxCell is also advancing Ovasave, a therapy for refractory Crohn's disease, having completed an initial study with positive outcomes and planning further clinical trials. The company collaborates with prominent research institutions, including the Lübeck Institute of Experimental Dermatology and the University of British Columbia, to enhance its research and development efforts. TxCell operates as a subsidiary of Sangamo Therapeutics, Inc., continuing its focus on innovative immunotherapy solutions.

TcLand Expression is a fully integrated company displaying high expertise in all stages of biomarker development: R&D, bioinformatics & biostatistics, clinical & regulatory , market access and production. TcLand Expression is a pioneer and European leader in personalized medicine in immunology (transplantation and auto-immune disorders) with a rich pipeline of biomarkers in development.

Innovative Silicon was founded to develop and commercialise Floating Body effect memory for SoC/MPU products used in diverse applications including handheld computers, games consoles, cellular communications devices, cameras. The company closed its first round of VC funding in 2003, completed its first 90nm megabit Z-RAM memory design in 2004 and its first 65nm designs in 2005. The company was founded in 2002 and is headquartered in Santa Clara, California with additional offices in Lausanne, Switzerland; and Yokohama, Japan.

Ekinops is a provider of advanced optical transport solutions tailored for service providers and private networks globally. The company specializes in its EKINOPS 360 platform, which is designed for a variety of applications, including metro, regional, and long-haul communications. Ekinops offers a range of carrier-grade solutions, including 10G, 100G, and 200G options that enhance data transport capacity. Its expertise in transmission, aggregation, and Forward Error Correction (FEC) enables operators to efficiently utilize dark fiber and various network technologies such as CWDM, DWDM, SONET/SDH, IP, and SAN networks.

NemeriX SA operates as a fabless semiconductor company that develops ultra-low-power, semiconductors, and software solutions for global positioning system and location-based service products. Its products include analog RF receivers, baseband, and indoor global positioning system integrates chips, as well as global positioning systems based integrated chipset. The company also offers OS support for WinCE, WinMobile, WinXP, LinuX, Symbian, and Nucleus; NeX, an extended ephemeris solution that enables mobile devices to acquire immediate positioning information in difficult garage scenarios and in harshest multi-path environments; SUPL client, which is inter-operated with several independent SUPL servers. In addition, it offers solutions to enable product integration, including evaluation boards, system software reference designs, user documentation, online support, and access to designers and global cadre of application engineers. The company’s product application areas include cellular phones, battery-powered wireless and handheld terminals, personal navigation devices, personal media players, and digital still cameras. It serves proximity-based marketing, social networking, gaming and financial authentication, navigation, tracking, and emergency markets. The company was founded in 2002 and is based in Manno, Switzerland. It has a design center in Cambridge, the United Kingdom; an applications center in Seoul, Korea; a technical center in Taipei, Taiwan; and sales offices in the United States, Europe, Taiwan, and Japan.

Median Technologies is a company that develops and markets software products and platforms for medical image analysis, focusing on oncology clinical trials and cancer screening. Founded in 2002 and based in Valbonne, France, it offers solutions such as iBiopsy, an AI-powered platform that aids in biomarker identification and patient profiling through CT scan similarity searches, and iSee, which facilitates image analysis and management in clinical trials. The company aims to standardize and automate the interpretation of medical images to enhance the diagnosis of cancer and evaluate treatment responses. Median Technologies serves both drug development and patient care markets, partnering with contract research organizations and Canon to deliver integrated imaging services and innovate new imaging technologies.

Implanet S.A., together with its subsidiaries, designs, manufactures, and sells implants for orthopedic surgery in France, the United States, Brazil, and internationally. The company offers spinal, arthroscopy, and knee products. Its products include Jazz, Jazz Passer, Jazz Cap SP, Jazz Lock, Jazz Claw, Jazz Standalone, Jazz Frame, and Jazz Screw systems for posterior fixation. The company also offers knee prostheses, such as Madison for conventional surgical techniques. Implanet S.A. was founded in 2006 and is based in Martillac, France.

Nautilus Biotech is a biotechnology company. The company has a pipeline of therapeutic proteins with improved profiles. The company's products include Belerofon, an injectable and orally available interferon alpha for use in the treatment of chronic Hepatitis C infection; and Vitatropin, an injectable and orally available human growth hormone (hGH) for use in the treatment of growth deficiencies. Nautilus Biotech S.A. sells therapeutic proteins, including interferons, hormones, growth factors, and enzymes in France and internationally. The company's protein engineering technology improves the pharmacology profile and administration route of blockbuster protein drugs. Nautilus Biotech S.A. was founded in 1999 and is based in Evry, France.

aveni, Inc. specializes in advanced metallization technologies for semiconductor applications, particularly in damascene through silicon vias and micro-electromechanical systems (MEMS). The company offers two primary technologies: Electrografting (eG), a wet electrochemical process that facilitates the growth of high-quality thin films on conducting surfaces, and Chemicalgrafting (cG), which is designed for non-conductive substrates. Both technologies are instrumental in enhancing device performance and yield, making them essential for modern semiconductor manufacturing. Founded in 2001 as a spinoff from the Commissariat à l’énergie atomique et aux énergies alternatives (CEA), aveni has established partnerships with various research and development centers, as well as leading global equipment and device manufacturers. The company operates from its headquarters in Massy, France, and leverages a skilled team of scientists and engineers with expertise in surface science, electrochemistry, and materials science to drive innovation in the field.

Theraptosis is a biopharmaceutical company that designs and develops various drugs for cancer and neurodegenerative diseases. It also offers research and development programs covering anti-angiogenesis, targeted tumor cell killing, auto-immunity, and neuroprotection. Theraptosis was founded in 2001 and is based in Romainville, France.

StreamCore is a prominent provider of visibility and performance control solutions designed for managing interactive applications and real-time communications, such as VoIP and video, over wide area networks (WAN) and local area networks (LAN). The company's products offer enterprises comprehensive visibility across network performance, applications, and communication channels, all accessible from a single centralized management console. StreamCore's solutions uniquely integrate visibility with advanced performance control, allowing for efficient monitoring and reporting. This integration enhances the management of application delivery and ensures rapid deployment while maintaining cost-effectiveness for organizations.

AlchiMedics is focused on the implementation of electro-grafting technology for implantable biomedical applications. Its technology is used for fast healing post drug-eluting-stent implantation procedures. AlchiMedics was founded in 2007 and is based in Massy, France.

Pharma Omnium is a French pharmaceutical company that markets mature drugs in various therapeutic classes. The company provides nutraceutical, dermatological, and dermo-esthetic products.

Nexthink S.A. is a leader in end-user experience management, focusing on enhancing digital workplaces through real-time analytics and employee feedback. The company provides a comprehensive platform that transforms endpoint data into actionable insights, enabling organizations to identify, diagnose, and resolve issues effectively. Its offerings include solutions for incident and problem management, change management, and a Digital Experience Score that combines quantitative data and user input to assess and enhance the digital workplace experience. Nexthink serves a diverse range of sectors, including education, finance, healthcare, and manufacturing, catering to Global 5000 organizations both in Switzerland and internationally. Established in 2004 and headquartered in Prilly, Switzerland, Nexthink operates across the United States, Europe, the Middle East, and Asia Pacific.